

SABRIL (vigabatrin)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

SABRIL is an anti-epileptic medication that inhibits the enzyme (GABA-T) which degrades GABA. There is no direct or consistent correlation between plasma concentration and efficacy.

Authorization: 1) Refractory complex partial seizures in adults, after several other medications have failed and in whom the potential benefits outweigh the risk of possible vision loss (see below). 2) Infantile Spasm as monotherapy for pediatric patients 1 month-2 years of age for whom the potential benefits outweigh the risk of possible vision loss.

Dosing: Initiate therapy with 1g/day (500mg twice a day), increased in weekly 500mg increments to 3g/day. Doses greater than 6g/day confer no advantage.

PRECAUTIONS: Special restricted distribution due to risk of progressive and permanent bilateral visual field constriction (SHARE program; 1-888-45-SHARE). Visual field testing required every 3 months. Increased risk of suicidal thinking (no greater than other antiepileptic medications). Somnolence and fatigue. Anemia. Peripheral neuropathy. Weight gain.

DRUG INTERACTIONS: caution with CNS depressants; may decrease serum concentration of phenytoin and fosphenytoin;

REFERENCES

National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at <http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf>. Accessed January 21, 2013.

Sabers A and Gram L, "Newer Anticonvulsants: Comparative Review of Drug Interactions and Adverse Effects," *Drugs*, 2000, 60(1):23-33.

Banin E, Shalev RS, Obolensky A, Neis R, Chowars I, Gross-Tsur V. Retinal function abnormalities in patients treated with vigabatrin. *Arch Ophthalmol* 2003;121(6):811-6.

Bruni J, Guberman A, Vachon L, Desforages C. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. *Seizure* 2000;9:224-32.

Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. *Cochrane Database Syst Rev* 2008;(3):CD007302.

Sills GJ. Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine. *Epileptic Disord* 2003;5(1):51-6.

Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. *Epilepsia* 1999;40:1627-33.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review